PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Antimicrobial efficacy of corneal cross-linking in vitro and in vivo for Fusarium solani: a potential new treatment for fungal keratitis.

Abstract Fungal keratitis is one of the major causes of visual impairment worldwide. However, the effectiveness of corneal collagen cross-linking (CXL) for fungal keratitis remains controversial. In this study, we developed an in vitro and an in vivo models to assess the efficacy of CXL for Fusarium keratitis.
PMID
Related Publications

Accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis.

Evaluation of Corneal Cross-Linking for Treatment of Fungal Keratitis: Using Confocal Laser Scanning Microscopy on an Ex Vivo Human Corneal Model.

Anterior segment optical coherence tomography in evaluation of severe fungal keratitis infections treated by corneal crosslinking.

Fusarium keratitis 3 weeks after healed corneal cross-linking.

Treatment of fungal keratitis from Fusarium infection by corneal cross-linking.

Authors

Mayor MeshTerms

Cross-Linking Reagents

Keywords

Antifungal therapeutic use

Corneal collagen cross-linking

Fungal keratitis

Fusarium solani

Mice

Journal Title bmc ophthalmology
Publication Year Start




PMID- 29499665
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20180309
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Mar 2
TI  - Antimicrobial efficacy of corneal cross-linking in vitro and in vivo for Fusarium
      solani: a potential new treatment for fungal keratitis.
PG  - 65
LID - 10.1186/s12886-018-0727-0 [doi]
AB  - BACKGROUND: Fungal keratitis is one of the major causes of visual impairment
      worldwide. However, the effectiveness of corneal collagen cross-linking (CXL) for
      fungal keratitis remains controversial. In this study, we developed an in vitro
      and an in vivo models to assess the efficacy of CXL for Fusarium keratitis.
      METHODS: The effect of in vitro CXL fungicidal was evaluated on the cultures of
      Fusarium solani which were exposed to irradiation for different durations.
      Viability of fungal was appraised under four conditions: no treatment (control); 
      CXL: UVA (365 nm)/riboflavin; riboflavin and UVA (365 nm). Each batch of sterile 
      plate culture was irradiated for different CXL durations. The in vivo Therapeutic
      effect was studied on a mouse keratitis model. The animals were divided randomly 
      into three groups: group A with no treatment (control); Group B with CXL
      treatment for two minutes and group C with CXL treatment for three minutes. The
      CXL procedure was performed 24 h post inoculation in each group. All mice with
      corneal involvement were scored daily for 7 days and 10 days after infection.
      Corneals were extracted at various time points for quantitative fungal recovery. 
      Histological evaluations were conducted to calculate the number of
      polymorphonuclear cells. RESULTS: Viability of fungal decreased significantly in 
      CXL group with 30-min irradiation compared with that in control, riboflavin and
      UVA groups (P < 0.01). The colony-forming units (CFUs) of fungal solutions in
      culture significantly decreased with CXL treatment (P < 0.05). Clinical scores,
      corneal lesion, corneal opacity, neovascularization and the depth of ulceration
      scores in group B and group C were remarkably lower than that in group A (P <
      0.05, P = 0.001, P = 0.001, P = 0.034 and P = 0.025 respectively). Scores of
      group C were much lower than that in group B. Histological revealed that
      destruction of corneal collagen fibers and infiltration of inflammatory cells
      into corneal tissue in group B and group C were much lower than that in group A. 
      CONCLUSIONS: We believe that CXL treatment may be applied to fungal keratitis,
      therapeutic efficacy will improve with longer treatment duration.
FAU - Zhu, Ziqian
AU  - Zhu Z
AD  - People's Hospital of Zhengzhou University and Henan Provincial People's Hospital,
      Henan Eye Institute, Henan Eye Hospital, Zhengzhou, 450003, China.
FAU - Zhang, Hongmin
AU  - Zhang H
AD  - People's Hospital of Zhengzhou University and Henan Provincial People's Hospital,
      Henan Eye Institute, Henan Eye Hospital, Zhengzhou, 450003, China.
FAU - Yue, Juan
AU  - Yue J
AD  - People's Hospital of Zhengzhou University and Henan Provincial People's Hospital,
      Henan Eye Institute, Henan Eye Hospital, Zhengzhou, 450003, China.
FAU - Liu, Susu
AU  - Liu S
AD  - People's Hospital of Zhengzhou University and Henan Provincial People's Hospital,
      Henan Eye Institute, Henan Eye Hospital, Zhengzhou, 450003, China.
FAU - Li, Zhijie
AU  - Li Z
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
FAU - Wang, Liya
AU  - Wang L
AUID- ORCID: http://orcid.org/0000-0002-2164-0512
AD  - People's Hospital of Zhengzhou University and Henan Provincial People's Hospital,
      Henan Eye Institute, Henan Eye Hospital, Zhengzhou, 450003, China.
      [email protected]
LA  - eng
GR  - 81670827/National Natural Science Foundation of China
GR  - 131PCXTD620/Zhengzhou City Project for Science and Technology Talents Team
      Construction Plan Science and Technology Innovation Team
GR  - 152102410085/Henan Province Science and Technology Research Project
PT  - Journal Article
DEP - 20180302
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Photosensitizing Agents)
RN  - 9007-34-5 (Collagen)
RN  - TLM2976OFR (Riboflavin)
SB  - IM
MH  - Animals
MH  - Anti-Infective Agents/*therapeutic use
MH  - Collagen/metabolism
MH  - Colony Count, Microbial
MH  - Corneal Stroma/*metabolism
MH  - Corneal Ulcer/*drug therapy/metabolism/microbiology
MH  - *Cross-Linking Reagents
MH  - Disease Models, Animal
MH  - Eye Infections, Fungal/*drug therapy/metabolism/microbiology
MH  - Fusariosis/*drug therapy/metabolism/microbiology
MH  - Fusarium/*drug effects/isolation & purification
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Photosensitizing Agents/therapeutic use
MH  - Riboflavin/therapeutic use
MH  - Ultraviolet Rays
PMC - PMC5833033
OTO - NOTNLM
OT  - Antifungal therapeutic use
OT  - Corneal collagen cross-linking
OT  - Fungal keratitis
OT  - Fusarium solani
OT  - Mice
EDAT- 2018/03/04 06:00
MHDA- 2018/03/10 06:00
CRDT- 2018/03/04 06:00
PHST- 2017/10/17 00:00 [received]
PHST- 2018/02/21 00:00 [accepted]
PHST- 2018/03/04 06:00 [entrez]
PHST- 2018/03/04 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
AID - 10.1186/s12886-018-0727-0 [doi]
AID - 10.1186/s12886-018-0727-0 [pii]
PST - epublish
SO  - BMC Ophthalmol. 2018 Mar 2;18(1):65. doi: 10.1186/s12886-018-0727-0.